CTXR
Citius Pharmaceuticals, Inc.
$0.58
-0.02 (-3.95%)
At close · Jul 7
Going-concern doubt
— flagged May 15, 2026
Substantial doubt about the company's ability to continue as a going concern.
“The accompanying unaudited consolidated financial statements have been prepared on a going concern basis, which contemplates the realization of assets and the satisfaction of liabilities in the normal course of business. We incurred a net loss of $37,503,635 for the six months ended March 31, 2026. The Company experienced negative cash flows from operations of $14,308,843 for the six months ended March 31, 2026. At March 31, 2026, the Company had $4,590,174 in cash and a negative working capital of approximately $23.3 million.”View the 10-Q filed May 15, 2026
Market Cap
$15.30M
Shares
27,452,570
Income-statement, balance-sheet and cash-flow figures extracted from the company's SEC filings — 10-K annual and 10-Q quarterly reports — and standardised for comparison across periods.
Revenue
$90K
0%
FY2022
Net Income
-$39.74M
-0.8%
FY2025
Gross Margin
0%
0pp
FY2018
Operating Margin
-37017.83%
-10871.3pp
FY2022
Diluted EPS
-$3.38
+43.4%
FY2025
Operating Cash Flow
-$26.55M
+5.8%
FY2025
Chart any reported metric, KPI or segment over time — the full statement history lives here
Search above to add metrics — fundamentals, product and segment revenue, company KPIs, valuation.
| Line Item | TTM | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 | FY2016 | FY2015 | FY2014 | FY2013 | FY2012 | FY2011 | FY2010 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| — | — | — | — | $90K | $90K | $90K | $90K | $75K | $50K | — | — | — | $0 | $0 | $0 | — | |
| — | — | — | — | — | — | — | — | — | — | $806 | $3066 | $555 | — | — | — | — | |
| — | — | — | — | — | — | — | — | $75K | $50K | $45K | — | — | — | — | — | — | |
| — | — | — | — | — | — | — | — | $0 | $0 | — | — | — | — | — | — | — | |
| — | — | — | — | — | — | — | — | 0% | 0% | — | — | — | — | — | — | — | |
| $1.63M | $9.16M | $11.91M | $14.82M | $17.66M | $12.24M | $8.81M | $8.6M | $6.56M | $2.94M | $2.93M | $1.8M | $574 | — | — | — | — | |
| $40.46M | $18.53M | $18.25M | $15.3M | $11.75M | $9.84M | $8.09M | $6.29M | $6.45M | $6.06M | $3.78M | $946.61K | $183.04K | $19.14K | $4059 | $12.19K | — | |
| — | — | — | — | — | — | — | — | — | $2632 | $1343 | $0 | — | — | — | — | — | |
| $62.93M | $38.53M | $42M | $36.73M | $33.32M | $23.53M | $17.71M | $15.6M | $13.79M | $9.99M | $7.45M | $3.23M | $653.8K | $88.87K | $19.62K | $25.64K | — | |
| -$58.44M | -$38.53M | -$42M | -$36.73M | -$33.32M | -$23.53M | -$17.71M | -$15.6M | -$13.79M | -$9.99M | -$7.45M | -$3.23M | -$653.8K | -$88.87K | -$19.62K | -$25.64K | — | |
| — | — | — | — | -37017.83% | -26146.55% | -19678.54% | -17331.51% | -18385.52% | -19972.62% | — | — | — | — | — | — | — | |
| — | — | — | — | — | — | — | — | — | -$9.98M | -$7.45M | -$3.23M | — | — | — | — | — | |
| — | $267.78K | — | — | — | $10.84K | $15.67K | $16.44K | $15.84K | $850.79K | $8994 | $7500 | $93.07K | — | $3092 | $704 | — | |
| $172.74K | $110.08K | $758K | $1.18M | $251.4K | $261.83K | $68.07K | $52.66K | — | — | $806 | $3066 | — | — | — | — | — | |
| $3.55M | -$157.7K | $3.15M | $4.77M | $251.4K | $477.46K | $162.6K | $36.22K | $1.25M | -$398.64K | -$846.41K | $327.66K | -$83.92K | — | — | -$704 | — | |
| — | — | — | — | — | — | $110.21K | — | — | — | — | — | — | — | — | — | — | |
| -$54.89M | -$38.68M | -$38.85M | -$31.97M | -$33.06M | -$23.05M | -$17.55M | -$15.56M | $12.54M | $10.38M | -$8.3M | -$2.9M | -$737.73K | -$95.22K | -$22.01K | -$26.34K | — | |
| $561.51K | $1.06M | $576K | $576K | $576K | $1233 | $741 | — | — | — | — | — | — | $0 | $0 | $0 | — | |
| -$55.45M | -$39.74M | -$39.43M | -$32.54M | -$33.64M | -$23.05M | -$17.55M | -$15.56M | -$12.54M | -$10.38M | -$8.3M | -$2.9M | -$737.73K | -$31.37K | -$22.01K | -$26.34K | -$15.5K | |
| — | — | — | — | -37378.5% | -25616.04% | -19497.87% | -17291.27% | -16715.52% | -20769.91% | — | — | — | — | — | — | — | |
| -$9.25M | -$2.31M | -$287K | — | — | — | — | — | — | — | — | — | — | — | — | — | — | |
| -$46.2M | -$37.43M | -$40.19M | -$33.69M | -$33.64M | -$24.51M | -$17.55M | — | — | — | — | — | — | — | — | — | — | |
| USD/shares | — | -$3.38 | -$5.97 | -$5.57 | -$5.75 | -$5.75 | — | — | — | — | — | — | — | $0.00 | $0.00 | $0.00 | — |
| USD/shares | — | -$3.38 | -$5.97 | -$5.57 | -$5.75 | -$5.75 | — | — | — | — | — | — | — | $0.00 | $0.00 | $0.00 | — |
| shares | — | 11.07M | 6.73M | 6.05M | 5.84M | 4.34M | 1.57M | 806.47K | 429.28K | 219.3K | 144.93K | 84.89K | 772.89K | 720K | 720K | 720K | — |
| shares | — | 11.07M | 6.73M | 6.05M | 5.84M | 4.34M | 1.57M | 806.47K | 429.28K | 219.3K | 144.93K | 84.89K | 772.89K | 720K | 720K | 720K | — |
Italic rows are computed from reported lines — open a row's info icon for its formula. Values reflect the latest filing (restatements included); per-share figures on today's split basis. Click a value for its source filing.
TTM: trailing twelve months through the latest reported quarter — flows sum the last four quarters, balances take the latest. 3Y/5Y/10Y columns are trailing CAGR from the newest fiscal year; blank where an endpoint is missing or negative.